MassBio CEO and President Kendalle Burlin O’Connell issued the following statement in response to the ruling by a federal judge in Texas to suspend the FDA’s approval of mifepristone:
“The judicial interference by a federal judge in Texas is not only an attack on access to basic medical care for women across the country, but it also threatens the very processes that have been established to deliver safe and effective treatments and therapies to patients. Our members face enough obstacles during the drug development process as it is. Injecting this type of uncertainty and non-scientific politics will have a significant impact on innovation and investment in medicines to address unmet medical needs. MassBio joins with our industry partners in calling for the immediate reversal of this decision and expressing our unequivocal support of the authority of the FDA that is based in science and statute.”
Kendalle Burlin O’Connell has also joined with the more than 100 leaders, investors, and other biotech employees at companies based in Massachusetts who have signed on to this letter.